Creavo Medical Technologies (Creavo) is pleased to announce the start of a new study at St George’s, University of London, led by Dr Elijah Behr.
The study will assess if Creavo’s magnetocardiography (MCG) device can identify Brugada syndrome (BrS) in patients, then use this information to classify a group at risk of sudden cardiac death (SCD).
Approximately 60 patients will be enrolled throughout the study, which is scheduled to be completed in the October timeframe.
Dr Behr, who is a Reader in Cardiovascular Medicine at St George’s University of London and consultant cardiologist at London’s St George’s Hospital, is a renowned specialist in the field of arrhythmias and SCD. He said: “This trial is one of the first to assess the potential use of MCG to identify patients at greater risk of sudden cardiac death. Only by exploring new technologies can we work to improve outcomes for patients, and we are very pleased to be undertaking this project.”
Steve Parker, Chief Executive Officer at Creavo said: “There is extensive research into the use of MCG to accurately rule out acute coronary syndrome in chest pain patients in an A&E setting, but this new study will help assess the potential for the device to be used as a screening tool outside of emergency care. This is an important step in our journey, and we thank the team at St George’s University for their involvement and support.”
St George’s is also involved in a separate multi-site study that is being conducted in the emergency department of several major UK hospitals located in Sheffield, Nottingham, Bristol and Leicester. That study will assess the effectiveness of Creavo’s device in aiding physicians identify patients at low risk of ischaemic heart disease.
There have been a number of notable achievements for Creavo in the last two years. The device received EC certification for CE marking in Europe in November 2016 and secured 510(k) clearance from the U.S. Food and Drug Administration in October 2017. Following initial funding for its MCG device, the company raised an additional £13.4m ($17m) in July 2017 from private equity investors. The round was oversubscribed and exceeded Creavo’s target, reflecting strong investor support and endorsement of the company’s strategy and team.